...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: USA ZHCLF investors

The way I originally looked at this is that there will be A and B shares once Zenith put out an IPO.

The A shares would be the preferred shares with a dividend attached to them or a reasonable facsimile in favour of the original RVX shareholders for holding down the fort, so to speak. But it is what it is.

 

Koo

Share
New Message
Please login to post a reply